Skip to content

Effect of long acting insulin in addition to standard treatment in management of diabetic ketoacidosis

Insulin Glargine supplementation during early management phase in children with Diabetic Ketoacidosis- A double blind Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/06/043076
Enrollment
82
Registered
2022-06-07
Start date
Unknown
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E101- Type 1 diabetes mellitus with ketoacidosis

Interventions

Intervention1: Glargine (long acting) insulin: Glargine Insulin supplementation (0.3U/kg) subcutaneously within 1 hour of initiation of regular insulin infusion. Every 24 hourly till resolution of DKA

Sponsors

Postgraduate Institute of Medical Education and Research PGIMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All children > 1 month to < 12 years with DKA will be enrolled

Exclusion criteria

Exclusion criteria: 1.Children with underlying liver disorders 2.Children with preexisting/ established renal disease 3.Children with symptomatic cerebral edema 4.Children with diagnosed or suspected inborn error of metabolism 5.Children who received glargine or long-acting insulin in past 24 hours

Design outcomes

Primary

MeasureTime frame
Time to resolution of acidosis(pH 7.3 and bicarbonate 15mmol/l), sensorium and closure of anion gapTimepoint: 28 days

Secondary

MeasureTime frame
Cost analysis of interventionTimepoint: Up to 28 days of enrollment;Incidence of hypokalemia and hypoglycemiaTimepoint: Till resolution of acidosis(pH 7.3 and bicarbonate 15mmol/l), sensorium and closure of anion gap;Incidence of rebound hyperglycemiaTimepoint: Up to 12 h after transition to subcutaneous short acting insulin;Length of PICU / hospital stayTimepoint: Up to 28 days of enrollment;Mean rate of blood glucose decreaseTimepoint: Till blood glucose falls to 250mg/dl;Proportion of in hospital all-cause mortalityTimepoint: Up to 28 days of enrollment;Total dose of regular insulinTimepoint: Till resolution of acidosis(pH 7.3 and bicarbonate 15mmol/l), sensorium and closure of anion gap

Countries

India

Contacts

Public ContactJayashree Muralidharan

PGIMER Chandigarh

mjshree@hotmail.com9815594343

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026